Jørgen Jespersen | Academic Influence

Jørgen Jespersen's AcademicInfluence.com Rankings

Jørgen Jespersen

Computer Science

#9090

World Rank

#9550

Historical Rank

Computational Linguistics

#2143

World Rank

#2165

Historical Rank

Machine Learning

#3896

World Rank

#3942

Historical Rank

Artificial Intelligence

#4227

World Rank

#4285

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Jørgen Jespersen's Degrees

PhD Computer Science Aarhus University
Masters Computer Science University of Copenhagen
Bachelors Computer Science University of Copenhagen

Similar Degrees You Can Earn

Why Is Jørgen Jespersen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jørgen Jespersen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. (1996) (591)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. (1993) (365)
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. (1985) (324)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. (2012) (220)
An extensive analysis of Y-chromosomal microsatellite haplotypes in globally dispersed human populations. (2001) (211)
Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. (1994) (197)
General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel (2014) (161)
Fibrin clot formation and lysis: basic mechanisms. (2000) (159)
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases (2007) (155)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. (2012) (129)
An international multicenter randomized study of computer‐assisted oral anticoagulant dosage vs. medical staff dosage (2008) (126)
A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. (1983) (120)
Low-fat, high-fiber diet favorably affects several independent risk markers of ischemic heart disease: observations on blood lipids, coagulation, and fibrinolysis from a trial of middle-aged Danes. (1994) (114)
A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. (1990) (113)
Are olive oil diets antithrombotic? Diets enriched with olive, rapeseed, or sunflower oil affect postprandial factor VII differently. (1999) (111)
Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. (1990) (110)
Genetic Influence on Inflammation Variables in the Elderly (2004) (109)
A Selective Depression of Tissue Plasminogen Activator (t-PA) Activity in Euglobulins Characterises a Risk Group Among Survivors of Acute Myocardial Infarction (1987) (109)
Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus (1995) (100)
Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. (1990) (96)
Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and fibrinolysis. (1993) (92)
Effect on blood lipids, coagulation, and fibrinolysis of a fat high in myristic acid and a fat high in palmitic acid. (1994) (90)
Longevity Is Independent of Common Variations in Genes Associated with Cardiovascular Risk (1999) (87)
Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. (1998) (86)
On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. (2009) (86)
Effects of dietary fat quality and quantity on postprandial activation of blood coagulation factor VII. (1997) (85)
Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. (1997) (79)
Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. (1993) (79)
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies (2018) (78)
Lipoprotein profile of a Greenland Inuit population. Influence of anthropometric variables, Apo E and A4 polymorphism, and lifestyle. (1992) (78)
The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. (2003) (77)
Laboratory Techniques in Thrombosis — a Manual (1999) (76)
Enhanced Effective Fibrinolysis following the Neutralization of Heparin in Open Heart Surgery Increases the Risk of Post-Surgical Bleeding (1990) (76)
Non-Fasting Factor VII Coagulant Activity (FVII:C) Increased by High-Fat Diet (1994) (74)
Genetic influence on thrombotic risk markers in the elderly – a Danish twin study (2006) (71)
Factor VII polymorphisms in populations with different risks of cardiovascular disease. (1997) (70)
European Concerted Action on Anticoagulation (2002) (70)
Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. (1996) (69)
Inflammation, thrombosis and atherosclerosis: results of the Glostrup study (2003) (68)
Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. (2002) (67)
Tissue‐type plasminogen activator and C‐reactive protein in acute coronary heart disease. A nested case–control study (2000) (66)
Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content. (1992) (64)
Depression of Tissue Plasminogen Activator (t-PA) Activity and Rise of t-PA Inhibition and Acute Phase Reactants in Blood of Patients with Acute Myocardial Infarction (AMI) (1987) (64)
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program (2009) (63)
Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1) (1993) (60)
Effect of fish diet versus meat diet on blood lipids, coagulation and fibrinolysis in healthy young men (1991) (60)
Increased Euglobulin Fibrinolytic Potential in Women on Oral Contraceptives Low in Oestrogen – Levels of Extrinsic and Intrinsic Plasminogen Activators, Prekallikrein, Factor XII, and C1-Inactivator (1985) (60)
Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods (2003) (59)
The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. (1992) (59)
Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. (2002) (57)
Gender-related association between beta-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit. (1995) (55)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. (1999) (55)
Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination (2004) (54)
World distribution of factor V Leiden mutation (1996) (54)
Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. (2004) (51)
A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. (1982) (50)
The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study. (2000) (47)
Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis. (1997) (45)
Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. (1988) (45)
Dietary Changes in Fasting Levels of Factor VII Coagulant Activity (FVII: C) Are Accompanied by Changes in Factor VII Protein and other Vitamin K-dependent Proteins (1995) (43)
Decreased Levels of Histidine-Rich Glycoprotein (HRG) and Increased Levels of Free Plasminogen in Women on Oral Contraceptives Low in Estrogen (1982) (43)
ECAT Assay Procedures A Manual of Laboratory Techniques (2012) (42)
Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. (2002) (42)
Chronic interstitial cystitis: increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin. (1983) (42)
The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. (1986) (41)
A multicentre randomised clinical endpoint study of parma 5 computer‐assisted oral anticoagulant dosage (2008) (41)
Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. (1990) (40)
Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. (1994) (39)
Factor VII-activating protease in patients with acute deep venous thrombosis. (2008) (39)
Inhibition of Tissue-Type Plasminogen Activator in Plasma of Women Using Oral Contraceptives and in Normal Women During a Menstrual Cycle (1986) (39)
Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women*† (1993) (39)
Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. (2006) (38)
Apolipoprotein E phenotype and blood pressure (1994) (38)
Associations between Aortic Calcification and Components of Body Composition in Elderly Men (2006) (38)
Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study (2003) (37)
The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate (2013) (37)
Antithrombin-III and platelets in haemodialysis patients. (1981) (37)
A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. (2006) (37)
European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point‐of‐care prothrombin time monitor systems (2002) (37)
Interrelationship between coagulant activity and tissue‐type plasminogen activator (t‐PA) system in acute ischaemic heart disease. Possible role of the endothelium (1990) (37)
Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity (1993) (36)
Minimum lyophilized plasma requirement for ISI calibration. European Concerted Action on Anticoagulation. (1998) (36)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
The cost‐effectiveness of computer‐assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study (2009) (33)
Post partum haemolytic-uraemic syndrome treated with antithrombin-III. (1981) (33)
Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study (2003) (32)
Report on the Dutch Consensus Development Meeting for Implementation and Further Development of Population Screening for Colorectal Cancer Based on FOBT (2005) (32)
Diet and blood coagulation factor VII—a key protein in arterial thrombosis (1998) (32)
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate. (1997) (31)
A simplified estimation of tissue plasminogen activator (t-PA) inhibition in human plasma (1987) (30)
The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. (2013) (30)
Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. (1991) (30)
Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of normal pregnancy (1995) (30)
A Functional Plasminogen Assay Utilizing the Potentiating Effect of Fibrinogen to Correct for the Overestimation of Plasminogen in Pathological Plasma Samples (1985) (29)
Characterization of Plasminogen Activators in Unstimulated and Stimulated Human Whole Saliva (1987) (28)
Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomised, placebo-controlled study (1992) (28)
The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays. (1982) (28)
Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients. (1988) (28)
Influence of Plasma Platelets on Activated Protein C Resistance Assay (1995) (28)
The European Concerted Action on Anticoagulation (ECAA): Field Studies of Coagulometer Effects on the ISI of ECAA Thromboplastins (1998) (27)
Fasting Serum Insulin Levels and Coronary Heart Disease in a Danish Cohort: 17-year Follow-up (1995) (27)
Subcutaneous heparin in the treatment of interstitial cystitis. (1985) (27)
European Concerted Action on Anticoagulation (ECAA) - The Multicentre Calibration of Rabbit and Human ECAA Reference Thromboplastins (1996) (27)
European concerted action on anticoagulation. Use of plasma samples to derive international sensitivity index for whole-blood prothrombin time monitors. (2002) (26)
Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women (2003) (26)
Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. (1990) (26)
Analytical and clinical validation of a new point-of-care testing system for determination of D-Dimer in human blood. (2010) (25)
Plasminogen Activator Inhibitor Type-1 Determines Plasmin Formation in Patients with Ischaemic Heart Disease (1995) (25)
The Diurnal Increase in Euglobulin Fibrinolytic Activity in Women Using Oral Contraceptives and in Normal Women, and the Generation of Intrinsic Fibrinolytic Activity (1986) (25)
Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. (2001) (25)
Comparison of local International Sensitivity Index calibration and ‘Direct INR’ methods in correction of locally reported International Normalized Ratios: an international study (2007) (25)
European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. (2004) (24)
Multivariate analysis of the relation between diet and warfarin dose (2012) (24)
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies (2011) (23)
New alleles in F7 VNTR. (1994) (23)
Plenty of pills: polypharmacy prevails in patients of a Danish anticoagulant clinic (2011) (23)
Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis (2008) (22)
The Possible Role of Oral Epithelial Cells in Tissue-type Plasminogen Activator-related Fibrinolysis in Human Saliva (1990) (22)
European Concerted Action on Anticoagulation (ECAA). An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors (2003) (22)
Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. (1999) (22)
Intraperitoneal Heparin Ameliorates the Systemic Inflammatory Response in PD Patients (2005) (22)
A comparison of the determination of glucosylated haemoglobin by isoelectric focusing and cation-exchange chromatography on minicolumns. (1986) (21)
The link between high-fat meals and postprandial activation of blood coagulation factor VII possibly involves kallikrein. (2000) (21)
Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy. (1991) (21)
Internal Quality Control of PCR-based Genotyping Methods in Research Studies and Patient Diagnostics (2002) (21)
Rise of plasma t‐PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide) (1989) (21)
Evidence for a Role of Factor XII‐dependent Fibrinolysis in Cardiovascular Diseases (1992) (20)
Individual Levels of Plasma α2-Antiplasmin and α2 Macroglobulin During the Normal Menstrual Cycle and in Women on Oral Contraceptives Low in Oestrogen (1983) (20)
Postpartum haemolytic-uraemic syndrome successfully treated with antithrombin III. (1980) (20)
Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women (2017) (19)
Effects on markers of inflammation and endothelial cell function of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals (2011) (19)
Dietary Factor VII Activation Does Not Increase Plasma Concentrations of Prothrombin Fragment 1+2 in Patients With Stable Angina Pectoris and Coronary Atherosclerosis (2000) (19)
Does long‐term angiotensin converting enzyme inhibition affect the concentration of tissue‐type plasminogen activator‐plasminogen activator inhibitor‐1 in the blood of patients with a previous myocardial infarction (1997) (19)
Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis (2007) (19)
Effects of methylamine and heparin on a rapid chromogenic assay of C1-esterase inhibitor in plasma. (1990) (18)
Contraception guidance in women with pre-existing disturbances in carbohydrate metabolism. (1996) (18)
Simplified method for international normalized ratio (INR) derivation based on the prothrombin time/INR line: an international study. (2010) (18)
European Concerted Action on Anticoagulation. A multicentre calibration study of WHO international reference preparations for thromboplastin, rabbit (RBT/90) and human (rTF/95) (2005) (18)
Effects of monophasic low‐dose oral contraceptives on fibrin formation and resolution in young women (1993) (18)
Reactive coagulation induced by plasmin in patients treated with recombinant tissue‐type plasminogen activator (1993) (17)
Observations during the treatment with antithrombin-III concentrate of a case of a tampon-related toxic shock syndrome and disseminated intravascular coagulation. Discrepancies between functional and immunologic determinations of antithrombin. (1982) (17)
The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition. (1986) (17)
Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease. (1985) (17)
A Sequential Study of Plasma Histidine-Rich Glycoprotein and Plasminogen in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis (1984) (17)
A Reference System Approach to Future Standardization of Laboratory Tests for Hemostasis, , (2002) (17)
The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima. (1993) (16)
Inhalation/intravenous recombinant tissue plasminogen activator and inhaled heparin in a patient with acute respiratory distress syndrome (1999) (16)
Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. (2014) (16)
Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. (1983) (16)
Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. (1993) (15)
Acquired activated protein-C resistance (1999) (15)
Regulation of tissue‐type plasminogen activator‐mediated fibrinolysis by plasminogen activator inhibitor type‐1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics (1994) (15)
European Concerted Action on Anticoagulation. Evaluation of a method for International Sensitivity Index calibration of two point-of-care prothrombin time (PT) monitoring systems (CoaguChek Mini and TAS PT-NC) with fresh plasmas based on whole-blood equivalent PT. (2002) (15)
The importance of "like to like" ISI calibrations with freeze dried plasmas. European Concerted Action on Anticoagulation. (1998) (15)
International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain (2018) (15)
Improved assay of antithrombin-III. Effects of certain additives on thrombin and on chromogenic peptide substrates. (1985) (14)
Plasminogen activator activity and plasma-coagulum lysis measured by use of optimized fibrin gel structure preformed in microtiter plates. (1995) (14)
The European Concerted Action on Anticoagulation (ECAA) Evaluation of a Set of Lyophilized Normal Plasmas to Establish the Normal Prothrombin Time for Coagulometer Systems (1998) (14)
Laboratory Techniques in Thrombosis. A Manual: 2nd revised edition of ECAT Assay Procedures (1999) (14)
Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy (2007) (14)
Termination of pregnancy in a woman with hereditary antithrombin deficiency under antithrombotic protection with subcutaneous heparin and infusion of plasma. (1981) (14)
European Concerted Action on Anticoagulation (ECAA): International Normalized Ratio Variability of CoaguChek and TAS Point-of-Care Testing Whole Blood Prothrombin Time Monitors (2002) (14)
The effect of sample size on fresh plasma thromboplastin ISI determination (1999) (14)
Disseminated intravascular coagulation in toxaemia of pregnancy. Correction of the decreased platelet counts and raised levels of serum uric acid and fibrin(ogen) degradation products by aspirin. (1980) (14)
Chronobiology of coronary risk markers in Greenland Eskimos: a comparative study with Caucasians residing in the same Arctic area. (1991) (13)
Does Low Protein Concentration of Tissue-type Plasminogen Activator Predict a Low Risk of Spontaneous Deep Vein Thrombosis? (1995) (13)
Postprandial coagulation activation in overweight individuals after weight loss: acute and long-term effects of a high-monounsaturated fat diet and a low-fat diet. (2014) (13)
Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives--a short review. (1996) (13)
A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. (2007) (13)
Evaluation of European Concerted Action on Anticoagulation lyophilized plasmas for INR derivation using the PT/INR line. (2011) (12)
European Concerted Action on Anticoagulation (ECAA): an assessment of a method for ISI calibration of two whole blood point‐of‐care PT monitor systems based on lyophilized plasmas using whole blood equivalent PT (2003) (12)
Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization. (2012) (12)
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. (1991) (12)
Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. (2003) (12)
Individual levels of plasma histidine-rich glycoprotein (HRG) during the normal menstrual cycle and in women on oral contraceptives low in oestrogen. (1982) (12)
Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo. (2011) (12)
Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy: a randomized, placebo-controlled study. (1991) (12)
The European Consensus Development Conference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from OC and HRT/ERT. (2003) (12)
Procoagulant activity and intimal dysfunction in IDDM (2006) (12)
European Concerted Action on Anticoagulation. Correction of displayed international normalized ratio on two point‐of‐care test whole‐blood prothrombin time monitors (CoaguChek Mini and TAS PT‐NC) by independent international sensitivity index calibration (2003) (12)
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors (2008) (12)
Absence of Prothrombin Mutation in Inuit (Greenland Eskimos) (1998) (12)
Assessment of endothelial function during oral contraception in women with insulin-dependent diabetes mellitus. (1994) (11)
Correction for Lack of Coincidence of Normal and Abnormal Calibration Slopes in ISI Determination (1999) (11)
INR derivation with the PT/INR Line simplified using a spreadsheet from the world wide web (2011) (11)
PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease. (1997) (10)
Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study. (1991) (10)
A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. (2005) (10)
Minimum numbers of fresh whole blood and plasma samples from patients and healthy subjects for ISI calibration of CoaguChek and RapidPointCoag monitors. (2002) (10)
On the Significance of Antithrombin-III, α2-Macroglobulin, α2-Antiplasmin, Histidine-Rich Glycoprotein, and Protein C in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis (1985) (10)
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal (2013) (10)
Vitamin K antagonists (2018) (10)
DNA-Polymorphisms and Plasma Levels of Vascular Disease Risk Factors in Greenland Inuit (1999) (10)
Antithrombin III and platelets during the normal menstrual cycle and in women receiving oral contraceptives low in oestrogen. (1983) (10)
Gender Differences in Fibrin Polymerization and Lysability of Fibrin in Patients with Atrial Fibrillation. (2016) (10)
A high-fat meal does not activate blood coagulation factor VII in minipigs (2001) (10)
Long-term effects on haemostatic variables of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals (2010) (10)
Effects of fish oil supplementation in late pregnancy on blood lipids, serum urate, coagulation and fibrinolysis. A randomised controlled study☆ (1994) (9)
Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: Results from the Danish Osteoporosis Prevention Study (DOPS) (2006) (9)
Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women (2010) (9)
Circadian variations of extrinsic fibrinolytic components in blood from eskimos (1990) (9)
Coagulometer international sensitivity index (ISI) derivation, a rapid method using the prothrombin time/international normalized ratio (PT/INR) Line: a multicenter study (2012) (9)
Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study. (1986) (8)
Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. (1989) (8)
No Effect of Unfractioned or Low Molecular Weight Heparin Treatment on Markers of Vascular Wall and Hemostatic Function in Incipient Diabetic Nephropathy (1997) (8)
Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal (2013) (8)
European concerted action on anticoagulation. Minimum numbers of lyophilized plasma samples for ISI calibration of CoaguChek and TAS point-of-care whole blood prothrombin time monitors. (2003) (8)
A simplified statistical method for local INR using linear regression (1997) (8)
Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution (2008) (8)
Fat consumption and factor VII coagulant activity. (1992) (8)
Induction and possible role of fibrinolysis in diabetes mellitus. (1991) (8)
Diabetes as a procoagulant condition (2002) (8)
Reduction of infarct size estimated enzymatically in patients with acute myocardial infarction after treatment with recombinant tissue type plasminogen activator or after spontaneous coronary recanalisation: A randomised, placebo controlled study (1990) (7)
Screening computer‐assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs (2009) (7)
Elevated Insulin Levels in Men: An 11-year Follow-up Study (1995) (7)
The protein concentration of blood coagulation factor VII can be measured equally well in plasma and serum. (1995) (7)
Estrogen receptor 1 haplotype does not regulate oral contraceptive-induced changes in haemostasis and inflammation risk factors for venous and arterial thrombosis. (2006) (7)
Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin III. (1989) (7)
Levels of protein S during the normal menstrual cycle and in women on oral contraceptives low in estrogen. (1989) (7)
Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke (2014) (7)
European Concerted Action on Anticoagulation (ECAA). Minimum number of centres for reliable International Sensitivity Index calibration of CoaguChek and TAS point-of-care whole blood monitors. (2002) (6)
Review: Diabetes as a procoagulant condition (2002) (6)
The risk of thrombosis in hereditary protein S deficiency in a Scandinavian family (1989) (6)
Increased fibrin formation in blood in women above the age of 30 who are both oral contraceptive users and smokers (1996) (6)
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease. (1997) (6)
Effect of Genomics on Venous Thrombosis: Relation to Sex Steroids (2006) (6)
Plasminogen activators in human nasal polyps and mucosa. (1997) (6)
Association between systemic generation of plasmin and activation of the factor XII-dependent fibrinolytic proactivator system in coronary thrombolysis (1992) (6)
Application of the UK NHS Improvement Anticoagulation Commissioning Support Document for ‘safety indicators’ in atrial fibrillation. Results of the European Action on Anticoagulation study (2012) (6)
Splanchnic extraction and clearance of tissue plasminogen activator (t-PA) after injection of recombinant t-PA (Actilyse®) in resting healthy subjects is proportional to the arterial concentration (2002) (6)
On the route to combined evidence from OC and HRT/ERT. (2002) (6)
Warfarin or dabigatran for treatment of atrial fibrillation (2014) (6)
Ecat Assay Procedures (a manual of laboratory techniques): European concerted action on thrombosis and disabilities of the commission of the European Communities (1993) (6)
Differences between functional and immunologic determinations of plasma antithrombin during the treatment of disseminated intravascular coagulation by infusion of antithrombin III concentrate. (1982) (6)
Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy (1996) (6)
Scientific and Standardization Committee Communication: A Reference System Approach to Future Standardization of (2001) (5)
Impact of point‐of‐care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non‐self‐monitoring patients: a cohort study: comment (2016) (5)
Degradation products of fibrin and of fibrinogen in synovial fluid and in plasma of patients with rheumatoid arthritis (1989) (5)
Detection of deep vein thrombosis following myocardial infarction by the technetium-99m-plasmin test (1983) (5)
On the diagnosis of deep venous thrombosis in patients at risk. (1984) (5)
α-linolenic acid and reduction of cardiac deaths (1994) (5)
Association of factor VII protein concentration with lifestyle factors. (1998) (5)
A delaying influence of cryoglobulins in the assessment of euglobulin fibrinolytic activity. (1986) (5)
Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study. (2003) (5)
A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements (2001) (4)
List of manufacturers (1992) (4)
The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors. (1997) (4)
Mean transit times and the sites of synthesis and catabolism of tissue plasminogen activator and plasminogen activator inhibitor type 1 in young subjects (2001) (4)
alpha-Linolenic acid and reduction of cardiac deaths. (1994) (4)
Introduction to diet and endogenous fibrinolysis (1994) (4)
PROPOSAL FOR A GENERAL STRATEGY OF STANDARDIZATION OF FIBRINOLYSIS ASSAYS TO BE USED IN CLINICAL PRACTICE (1999) (4)
The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus (1994) (4)
Venous occlusion test in fibrinolysis assays (1992) (4)
Balance of coagulation activity with fibrinolysis during use of oral contraceptives in women with insulin-dependent diabetes mellitus. (1995) (4)
Gaps Between the Present Assay Practice in Haemostasis and Clinical Chemistry Laboratories (1990) (4)
Is Factor VII Protein Concentration (FVII:Ag) a Thrombotic Risk Indicator? (1998) (4)
Plasma concentrations of blood coagulation factor VII measured by immunochemical and amidolytic methods (2000) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
An assessment of a method for ISI calibration of two whole blood point-of-care PT monitor systems based on lyophilised plasmas using whole blood equivalent PT (2003) (4)
Internal quality control of PCR-based genotyping methods: practical experiences. (2002) (4)
Quality assessment of coaguchek monitors: comparative analysis of the ECAA and conventional external QA (2007) (4)
Local international normalised ratio (INR) derivation simplified using the European concerted action on anticoagulation (ECAA) prothrombin time/INR line. (2011) (4)
PI A1/A2 polymorphism of platelet glycoprotein Illa and risk of cardiovascular disease (1997) (4)
[Food intake of Danes and cardiac risk factors]. (1995) (3)
Anticoagulant Properties of Rabbit Lungs in Tissue Thromboplastin-induced Intravascular Coagulation (1997) (3)
HOW TO DETECT DEFECTS OF TISSUE PLASMINOGEN ACTIVATOR IN THROMBOSIS-PRONE PATIENTS. AN INTRODUCTION TO DISCUSSION (1988) (3)
A comparison of the effects of cimetidine and epsilon-aminocaproic acid on fibrinolysis induced by activators of plasminogen and on fibrin formation. (1981) (3)
Hormone replacement therapy - estrogen and progestin effects on plasma C-reactive protein. (2002) (3)
Lack of hepatic metabolism of C-telopeptides of type I collagen. (2006) (3)
Specific, sensitive, precise, and rapid functional chromogenic assay of activated first complement component (C1) in plasma. (1990) (3)
Introduction to laboratory assays in haemostasis and thrombosis (1999) (3)
Various approaches to standardization and the importance of measurement accuracy (1996) (3)
Cholesterol-lowering, simvastatin, and coronary heart disease (1995) (3)
Plasma HMW fibrinogen in patients with ischaemic heart disease. (1990) (3)
Modification of the Immediate Plasmin Inhibition Assay to Secure Linearity of the Reference Curve with the Chromogenic Substrate S-2251 (1984) (3)
Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen (1991) (3)
Metabolic aspects of oral contraceptives of relevance for crdiovascular disease (1990) (3)
Protection against venous thrombosis in an antithrombin-III deficient patient suffering from episodes of arterial thrombosis requiring major surgery. Effects of oral stanozolol in combination with subcutaneous heparin and intravenous AT-III. (1985) (3)
Diet, gender, and plasma thrombomodulin. (1996) (2)
PIA1/A2 POLYMORPHISM OF PLATELET GLYCOPROTEIN IIIA AND RISK OF CARDIOVASCULAR DISEASE. AUTHORS' REPLY (1997) (2)
The transient transfer of plasma antithrombin-III to an extraplasmatic body compartment during haemodialysis. (1981) (2)
Monoclonal Antibodies Against Fibrinogen, Fibrin and Their Fragments (1985) (2)
Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysis. (1984) (2)
Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients. (1992) (2)
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study* (2001) (2)
Metabolic effects of oral contraceptives. (1970) (2)
Decreased synthesis of tissue plasminogen activator antigen in users of oral contraceptives (2000) (2)
In vitro effects of heparin and tissue factor pathway inhibitor on factor VII assays. Possible implications for measurements in vivo after heparin therapy (2000) (2)
Elevated Plasma Concentrations of Fibrinogen May Cause an Overestimation of Functional Plasminogen (1989) (2)
Deviations in factor XII-dependent plasminogen activator activity in relation to ischaemic heart disease and age (1992) (2)
Renal diseases, disseminated intravascular coagulation, and antithrombin III. (1983) (2)
Low-fat/high-fiber diets and coagulation/fibrinolysis. (1996) (2)
A study of the transient increase in blood fibrinolytic activity during haemodialysis (1987) (2)
Minimum numbers of ECAA lyophilized plasmas for ISI calibration of CoaguChek and TAS point-of-care whole blood prothrombin time monitors (2003) (2)
321 Secretion of protein-C and plasminogen by human hepatocytes: Influence of hormones (1988) (2)
PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System (2000) (2)
LIVER BIOPSY IN RELATION TO HAEMOSTASIS TESTS AND BLEEDING RISK (1988) (1)
FIBRINOLYSIS AND RECURRENCE OF MYOCARDIAL INFARCTION (1987) (1)
Circadian variation of fibrinolytic activity among Eskimos in Greenland. (1989) (1)
A comparison of linear and orthogonal regression analysis for local INR determination in ECAA coagulometer studies. European Concerted Action on Anticoagulation. (1998) (1)
European Action on Anticoagulation (EAA) evaluation of the UK National Health Service Improvement Guidelines for "Safety Indicators" in Anticoagulation of atrial fibrillation (2012) (1)
variables, Apo E and A4 polymorphism, and lifestyle Lipoprotein profile of a Greenland Inuit population. Influence of anthropometric (2011) (1)
DIAGNOSIS OF DEEP-VEIN THROMBOSIS (1984) (1)
Variable depletion of endogenous factor XII-dependent fibrinolytic activity following thrombolytic therapy of myocardial infarction and its relation to reinfarction. (1992) (1)
Effects of surfactants or aprotinin on antithrombin III assay. (1987) (1)
The effect of gliclazide on plasma urokinase-related fibrinolysis. The results from an exploratory study (1994) (1)
Meal-induced factor VII activation and thrombin formation in atherosclerotic patients (2000) (1)
The effect of ageing and hormone replacement therapy on glucose metabolism. (2006) (1)
Different response of the hemostatic system to oral contraception in diabetic and non-diabetic women (1996) (1)
Fibrinolysis and the Thrombotic Tendency (1984) (1)
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase Enhancement. (2001) (1)
Efectos metabólicos de los anticonceptivos orales (1993) (1)
IS THE ACTIVITY OF TISSUE-TYPE PLASMINOGEN ACTIVATOR (t-PA) OF CLINICAL RELEVANCE IN THROMBOPHILIA CAUSED BY PROTEIN S DEFICIENCY? (1988) (1)
Age standardization in the comparison of groups. Remaining problems illustrated by a comparison between a Greenland Eskimo population and a danish population (1992) (1)
A spectroscopic microtiter fibrin plate assay (1994) (1)
Factor XII dependent fibrinolytic activity is decreased in the acute phase of myocardial or cerebral infarction (1996) (1)
Launch of external quality assessment for CoaguChek monitors by the European Concerted Action on Anticoagulation (2011) (1)
A national field study of quality assessment (qa) og coaguchek monitors (2007) (1)
CHRONIC INTERSTITIAL CYSTITIS AND SUBCUTANEOUS HEPARIN (1985) (1)
Prothrombin fragment 1+2, a marker of thrombin formation, is related to transcapillary escape rate of albumin in insulin-dependent diabetic patients (1993) (1)
Thrombosis, disseminated intravasclar coagulation, and the dynamic haemostatic balance. Aspects of prophylaxis and treatment (1984) (1)
Effects of an oral antidiabetic drug (gliclazide) on inhibition of coagulation and fibrinolysis studied in insulin-treated diabetic patients (type I) (1989) (1)
No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids. (1996) (1)
Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus A sign of vascular damage in patients with diabetic nephropathy? (1999) (1)
Metabolic aspects of oral contraceptives of relevance for cardiovascular disease. First European conference on sex steroids and metabolism. (1990) (1)
Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
Lowering of the dosage of intravenous heparin hemodialysis by priming with subcutaneous heparin. (1981) (1)
Diagnosis of deep-vein thrombosis. (1984) (1)
Intraperitoneal heparin ameliorates the systemic inflammatory response in peritoneal dialysis patients. (2005) (1)
The effect of monophasic oral contraceptive regimens on Factor VII-activating Protease - a randomized multicentre study (2009) (1)
Influence of the VKORC1 3730 G > A polymorphism on warfarin dose (2013) (1)
[Hemostatic balance during treatment with the newest contraceptives]. (1994) (1)
allele in the 330 Japanese people in our study suggests that this allele does not have an important role in the risk of cardiovascular events in Japan. (1997) (0)
The authors of the article cited above respond (2007) (0)
[Thrombosis-precipitating factors and diagnosis in a patient with qualitative antithrombin III defect]. (1988) (0)
[Postmenopausal hormone replacement therapy--is there a cause of worry?]. (2002) (0)
Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid (1991) (0)
Standardization of Coagulation and Fibrinolysis Methods (2000) (0)
ID: 203 The Effects of Oral Contraceptives on Plasma - Studied by Proteomics. (2006) (0)
3P-0909 Aortic calcification (AC) and cardiovascular risk factors in middle-aged and elderly men (2003) (0)
The − 174 G / C variant of IL 6 as risk factor for mortality and technique failure in a large cohort of peritoneal dialysis patients (2012) (0)
Diagnostic performance of AQT90 FLEX D-Dimer in patients suspected for deep venous thrombosis - comparison with four well-established D-Dimer tests (2009) (0)
Thrombosis and Haemostasis (2010) (0)
CHANGES IN t-PA ACTIVITY AND INHIBITION AS PART OF THE ACUTE PHASE REACTION IN ACUTE MYOCARDIAL INFARCTION (1987) (0)
Evaluation of a method for ISI calibration of two point-of-care test (POCT) prothrombin time (PT) monitor systems (CoaguChek Mini and TAS PT-NC) with fresh plasmas based on whole blood equivalent PT (2002) (0)
On the in-vivo ex-vivo threshold: significant IPE associated with human blood sampling and handling (2004) (0)
Thrombosis prophylaxis for Oral and Maxillofacial surgery patients under general anaesthesia. Suggestions for individual risk assessment model and prevention (2022) (0)
in dietary fat content Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction (2011) (0)
Oral contraceptives increase plasma resistance against activated protein C in women with insulin-dependent diabetes mellitus (1996) (0)
Polypharmaci prevails among patients attending an anticoagulant clinic (2010) (0)
Inflammation and thrombosis: Historical aspects (2004) (0)
Low rates of stroke and major bleeding in patients treated with vitamin K antagonists in an anticoagulant clinic (2016) (0)
Patient knowledge in a high quality anticoagulant clinic (2015) (0)
Influence of blood handling on determination of plasma resistance against activated protein C (1996) (0)
A multicentre randomised clinical end-point study of PARMA 5 computer-assisted oral anticoagulant dosage: On behalf of the European Action on Anticoagulation (2008) (0)
A lack of coupling between the expression of the UK and the t-PA/PAI-1 systems in patients with acute ischaemic hart disease (1990) (0)
COST-EFFECTIVENESS OF COMPUTER-ASSISTED ANTICOAGULANT DOSAGE CLINICAL STUDY (2007) (0)
The European Action on Anticoagulation (EAA) Prothrombin Time/Intertnational Normalised Ratio Line - A new method of deriving local ISI and MNPT for use with coagulometers (2012) (0)
Contents, Vol. 16, 1986 (1986) (0)
Alterations of the tissue-factor induced coagulation pathway and the hemostatic balance by hormone replacement therapy (HRT) (2003) (0)
F192 HRT and CVD: Progestin induced chances in lipid metabolism may be counterbalanced by a long-cycle strategy (1996) (0)
Technology Implementation Plan (eTIP). European action on anticoagulation (EAA): cost-effectiveness of computer-assisted dosage (EAA computer-dosage)(QLG4-CT-2002-02175). (2015) (0)
fibrinolysis inhibitor alpha-2-antiplasmin in blood The mutual relationship between the two molecular forms of the major (2011) (0)
[Plasma fibrinogen and cardiovascular disease]. (1991) (0)
Visualization of The Procoagulant Effects of Combined Oral Contraceptives (COCs) (2018) (0)
[Deep venous thrombosis in patients with acute myocardial infarction diagnosed by the 99mTc-plasmin test]. (1983) (0)
BRIEF COMMUNICATION THE TRANSIENT TRANSFER OF PLASMA ANTITHROMBIN-III TO AN (1981) (0)
[Protein C deficiency and thrombosis. Physiological and clinical aspects]. (1986) (0)
The influence of VKORC! 3730 G>A polymorphism on warfarin dose (2013) (0)
Association of vessel wall changes with cardiovascular risk markers in healthy individuals (2014) (0)
Primary care Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods (2003) (0)
[Hormone replacement therapy in menopause and cardiovascular disease]. (2002) (0)
Hyperglycemia, hyperinsulinemia and inflammation in type II diabetics are associated with specific deviations in haemostatic variables (1999) (0)
Nye veje i standardisering/harmonisering af centrale variabler i det hæmostatiske system: The Joint IFCC/ISTH-SSC Committee on the Standardization of Coagulation Tests - Questions and Answers (2000) (0)
Artificially depleted plasmas are not necessarily commutable with native patient plasmas for International Sensitivity Index calibration and International Normalized Ratio derivation: a reply (2012) (0)
A new automated method for continuous registration of factor VII activation in vitro. Activation is accelerated by the concentration of factor VII and the activity state of the protein. (1994) (0)
[Diagnostic and clinical aspects in patients with acquired circulating coagulation inhibitors]. (1985) (0)
Metabolic effects of progestins (2004) (0)
Risk perception of stroke in atrial fibrillation patients does not correlate with clinical stroke risk (2013) (0)
Multivariate analysis of the relation between diet and warfarin dose (2011) (0)
Effectiveness and safety of vitamin K-antagonists in an anticoagulant clinic. (2016) (0)
Subject Index, Vol. 16, 1986 (1986) (0)
Clinical and biochemical aspects of the haemostatic balance in relation to development and prevention of cardiovascular diseases (2004) (0)
Cholesterol ester transfer protein (CETP) levels in patients with suspected deep venous thrombosis (2010) (0)
Standardization of Measurement of Components of the Fibrinolytic System - Introduction and Current Status (2000) (0)
Comparison of nine different blood collection tubes for contact activation of coagulation (2017) (0)
The assay of factor Xa on a centrifugal analyzer. (1984) (0)
Multivariate analysis of genetic, behavioural and socio-psychological determinants of vitamin K-antagonist dose (2011) (0)
Estrogen receptor-1 genotypes do not influence baseline levels of hemostasis and lipid risk markers for cardiovascular disease in young women (2006) (0)
Infusion of 1-desamino-8-d-arginine demonstrates that increased plasminogen activator inhibitor activity is responsible for impaired fibrinolysis in patients with ischaemic heart disease (1994) (0)
Influence of the VKORC1 3730 G > A polymorphism on warfarin dose (2012) (0)
367 Potential increases of the inhibition of coagulation and lysis of fibrin in type I diabetics receiving a second generation sulphonyl urea (1988) (0)
Loose fibrin structure and enhanced lysability in patients with atrial fibrillation and stroke (2014) (0)
Peroral AK-behandling (2010) (0)
Ageing and fibrinolysis (1992) (0)
Plasminmedieret aktivering af koagulationssystemet. [Plasmin mediated activation of coagulation in patients receiving recombinant tissue plasminogen activator] (1994) (0)
Urokinase-type plasminogen activator (u-PA) and the risk of coronary events in patients with angina pectoris (AP) (1998) (0)
Multivariate analysis of the relation between diet and vitamin K-antagonists (2011) (0)
Thyroid hormones T 3 and T 4 and their relationship with fibrinolysis variables (2010) (0)
Oral contraceptives and diabetes mellitus (1996) (0)
The interrelation between coagulant activity and the t-PA system in ischaemic heart disease. Possible involvement of the endothelium (1990) (0)
Cardiovascular risk factors are associated with subclinical atherosclerosis in healthy individuals – A DanRisk Substudy. EuroPrevent, Amsterdam April. P645 (2014) (0)
Inflammation in type II diabetics is not a major determinant of cardiovascular risk variables (2001) (0)
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]. (1994) (0)
Reply to B Lipinski (1995) (0)
World distribution of factor V Leiden mutation. (1996) (0)
Ageing and fibrinolysis - panel discussion (1992) (0)
Plasminogen activator inhibitor-1 and levels of sex hormone binding globulin in young women (2008) (0)
The thrombogenic effect of haemodialysis assessed by its influence on clot retraction, platelet volume, and platelet number (2016) (0)
Standardization of coagulation and fibrinolysis methods. The Editors Column (2000) (0)
Original research article A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 Ag of ethinylestradiol and 100 Ag of levonorgestrel with 30 Ag of ethinylestradiol and 100 Ag of levonorgestrel B (2005) (0)
THE EFFECT OF HORMONE THERAPY ON PLASMA MEASURES OF FACTOR VII-ACTIVATING PROTEASE IN YOUNGER POSTMENOPAUSAL WOMEN (2009) (0)
HRT and inflammatory mediators: progestin effects on c‐reactive protein and fibrinogen (2000) (0)
Evaluation of a Method for International Sensitivity Index Calibration of Two Point-of-Care Prothrombin Time (PT) Monitoring Systems with Fresh Plasmas Based on Whole-Blood Equivalent PT (2002) (0)
Intraperitoneal low molecular weight heparin increases PCR in PD patients (2010) (0)
The influence of genes, diet, physical activity and socio-psychological factors on vitamin K-antagonist dose (2011) (0)
Depletion of the Factor XII-dependent Proactivator System of Fibrinolysis During Thrombolytic Therapy (1993) (0)
Can Protein C and Protein S deficiency patients be identified during stable oral anticoagulant treatment (2009) (0)
DAWN as a tool in scientific projects (2010) (0)
TAFI antigen and plasminogen concentrations in plasma: study in plasminogen deficiency (2001) (0)
Editorial. Proceedings of the 3rd European Consensus Development Conference on Sex Steroids and Cardiovascular Diseases. November (2004) (0)
Progestogens in HT: Sufferance or desire? (2008) (0)
INR – Simplified: The Prothrombin Time/International Normalised Ratio (PT/INR) Line. (2011) (0)

This paper list is powered by the following services:

Other Resources About Jørgen Jespersen

portal.findresearcher.sdu.dk

What Schools Are Affiliated With Jørgen Jespersen?

Jørgen Jespersen is affiliated with the following schools: